PARIS--ExonHit Therapeutics has entered into a two-year collaborative agreement with the drug-discovery company Cerep here. The partners will develop new methods for toxicity assessments, target validation, and drug discovery. Central to the agreement is ExonHit's proprietary Differential Analysis of Transcripts Alternatively Spliced (DATAS) technology. Under terms of the agreement, Cerep will make an equity investment of $500,000 in ExonHit and will fund research expenses up to $2.3 million based on the achievement of specific research and development milestones.
ExonHit is a qualitative gene profiling company started up here a year ago by three former Rhone-Poulenc Rorer R&D managers. The company received venture funding from CDC Innovation, Oxford BioSciences Partners, and Sofinnova Partners.